Amarin Corp Plc (AMRN)

[rosemountbomber]

Thanks for posting. I liked the non-derogatory comment concerning RESPECT EPA:

“Most recently, the RESPECT EPA trial (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid) investigated the effects of 1.8 g/d IPE in Japanese patients with documented coronary artery disease and a low EPA/AA ratio at baseline. This study showed a 21% reduction in major adverse cardiovascular events (hazard ratio, 0.79 [0.62–1.00]) concomitant with significant increases in both EPA levels and the EPA/AA ratio.30 Post hoc evaluation of patients in each arm who did (IPE arm) and did not (control arm) achieve increases in EPA levels showed a significant reduction in the primary end point. Together, these data suggest that targeting the EPA/AA ratio as a modifiable risk factor in ASCVD prevention warrants further investigation with IPE. By increasing EPA levels, IPE treatment may favor a balance between pro-inflammatory and pro-resolving oxylipins implicated in atheroma development to augment the other direct cardioprotective mechanisms of EPA.1”